173 related articles for article (PubMed ID: 11190490)
21. Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest.
Santos-Argumedo L; Gordon J; Heath AW; Howard M
Cell Immunol; 1994 Jul; 156(2):272-85. PubMed ID: 7517793
[TBL] [Abstract][Full Text] [Related]
22. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy of human B-cell chronic lymphocytic leukemia in nude mice.
Zhu Z; Ghose T; Hoskin D; Lee CL; Fernandez LA; Lee SH; Mammen M
Cancer Res; 1994 Oct; 54(19):5111-7. PubMed ID: 7923127
[TBL] [Abstract][Full Text] [Related]
24. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
Buchsbaum DJ; Wahl RL; Glenn SD; Normolle DP; Kaminski MS
Cancer Res; 1992 Feb; 52(3):637-42. PubMed ID: 1732052
[TBL] [Abstract][Full Text] [Related]
25. The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma.
Schiele J; Knox SJ; Ruehl W; Goris ML
Radiother Oncol; 1992 Jul; 24(3):169-76. PubMed ID: 1410571
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
28. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
29. Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
Vervoordeldonk SF; Balkenende AY; van den Berg H; von dem Borne AE; van der Schoot CE; Van Leeuwen EF; Slaper-Cortenbach IC
Cancer Immunol Immunother; 1996 Jan; 42(1):24-30. PubMed ID: 8625363
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies.
White CA; Halpern SE; Parker BA; Miller RA; Hupf HB; Shawler DL; Collins HA; Royston I
Blood; 1996 May; 87(9):3640-9. PubMed ID: 8611688
[TBL] [Abstract][Full Text] [Related]
31. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
32. Optimal timing of administration of hyperthermia in combined radioimmunotherapy.
Kinuya S; Yokoyama K; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Bunko H; Michigishi T; Tonami N
Cancer Biother Radiopharm; 2000 Aug; 15(4):373-9. PubMed ID: 11041022
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Pagel JM; Pantelias A; Hedin N; Wilbur S; Saganic L; Lin Y; Axworthy D; Hamlin DK; Wilbur DS; Gopal AK; Press OW
Cancer Res; 2007 Jun; 67(12):5921-8. PubMed ID: 17575162
[TBL] [Abstract][Full Text] [Related]
34. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
35. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
38. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
39. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy.
Du Y; Honeychurch J; Cragg MS; Bayne M; Glennie MJ; Johnson PW; Illidge TM
Blood; 2004 Feb; 103(4):1485-94. PubMed ID: 14576070
[TBL] [Abstract][Full Text] [Related]
40. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.
Shih L; Ong GL; Burton J; Mishina D; Goldenberg DM; Mattes MJ
Cancer Immunol Immunother; 2000 Jul; 49(4-5):208-16. PubMed ID: 10941903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
